Physician profile
John D Arnett
NPI 1225021678
$13,578.61
in general payments reported to CMS, 2019-2025
55 companies · $2,523 in 2025
The $2,523 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $1,406 · 2021: $2,156 · 2022: $1,880 · 2023: $2,064 · 2024: $2,434 · 2025: $2,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,897 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,896.65 |
| Education | $123.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,346.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,214.22 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,091.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,029.21 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Amgen INC. | $949.02 | 2019-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $816.11 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $591.77 | 2019-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $571.80 | 2023-2025 | Korlym |
| Astellas Pharma US INC | $515.72 | 2019-2024 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $476.44 | 2019-2025 | Injectafer |
| Sunovion Pharmaceuticals INC. | $467.86 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $402.88 | 2020-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $362.21 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $291.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $263.58 | 2019-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.60 | 2019-2025 | Jardiance, Synjardy |
| Mylan Specialty L.P. | $241.36 | 2021-2024 | Yupelri |
| Electromed, INC. | $220.33 | 2019-2022 | |
| Allergan, INC. | $207.68 | 2019-2020 | |
| Lilly USA, LLC | $188.59 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $169.87 | 2019-2023 | Verquvo, Belsomra |
| Sumitomo Pharma America, INC. | $161.87 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $132.95 | 2022-2025 | |
| Alkermes, INC. | $120.00 | 2024 | Lybalvi |
| Axsome Therapeutics, INC. | $117.19 | 2024-2025 | Auvelity |
| Nestle Healthcare Nutrition INC. | $110.39 | 2020-2021 | |
| Amarin Pharma, INC. | $95.55 | 2019-2021 | |
| Antares Pharma, INC. | $92.32 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Exact Sciences Corporation | $90.79 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $78.10 | 2022-2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $76.61 | 2020-2025 | |
| Halozyme INC | $70.50 | 2023 | |
| Lundbeck LLC | $69.30 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $66.79 | 2019-2024 | Eliquis, Camzyos |
| Biohaven Pharmaceutical Holding Company LTD. | $64.77 | 2022 | |
| Horizon Therapeutics Plc | $59.24 | 2022-2023 | Krystexxa |
| Dexcom, INC. | $45.52 | 2024-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $45.06 | 2019-2021 | |
| Ardelyx, INC. | $44.61 | 2025 | Ibsrela |
| Inspire Medical Systems, INC. | $40.96 | 2025 | Inspire |
| Aimmune Therapeutics, INC. | $37.90 | 2024-2025 | Zenpep |
| Vanda Pharmaceuticals INC. | $36.78 | 2025 | Fanapt |
| Opko Pharmaceuticals, LLC | $29.82 | 2023 | Rayaldee |
| Regeneron Healthcare Solutions, INC. | $28.10 | 2022 | |
| Esperion Therapeutics, INC. | $28.01 | 2022-2023 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $25.84 | 2020-2021 | |
| Braemar Manufacturing, LLC | $23.20 | 2019 | |
| Ironwood Pharmaceuticals, INC | $19.24 | 2020 | |
| Boston Scientific Corporation | $18.30 | 2022 | |
| Avanir Pharmaceuticals, INC. | $17.66 | 2021 | |
| Baxter Healthcare | $16.19 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Gilead Sciences, INC. | $14.96 | 2019 | |
| Valeritas, INC. | $13.85 | 2019 | |
| Organogenesis INC. | $13.16 | 2023 | Puraply |
| Biohaven Pharmaceuticals, INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Arnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.